Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant Mycobacterium aurum

Rui Pi, Qingyun Liu, Howard E. Takiff, Qian Gao
Rui Pi
aKey Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Shanghai Public Health Clinical Center Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingyun Liu
aKey Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Shanghai Public Health Clinical Center Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard E. Takiff
bIntegrated Mycobacterial Pathogenomics Unit, Institut Pasteur, Paris, France
cDepartment of Tuberculosis Control and Prevention, Shenzhen Nanshan Centre for Chronic Disease Control, Shenzhen, China
dInstituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qian Gao
aKey Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Shanghai Public Health Clinical Center Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Qian Gao
DOI: 10.1128/AAC.00224-20
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We isolated spontaneous levofloxacin-resistant strains of Mycobacterium aurum to study the fitness cost and compensatory evolution of fluoroquinolone resistance in mycobacteria. Five of six mutant strains with substantial growth defects showed restored fitness after being serially passaged for 18 growth cycles, along with increased cellular ATP level. Whole-genome sequencing identified putative compensatory mutations in the glgC gene that restored the fitness of the resistant strains, presumably by altering the bacterial energy metabolism.

INTRODUCTION

Third-generation fluoroquinolones (FQs) levofloxacin and moxifloxacin play a critical role in the treatment of multidrug-resistant tuberculosis (1), and the development of fluoroquinolone resistance (FQ-R) in Mycobacterium tuberculosis dramatically reduces the rates of treatment success (2). FQs inhibit the action of DNA gyrase, which is composed of two A and two B subunits, encoded by gyrA and gyrB, respectively (3). Mutations in two short regions of gyrA and gyrB, known as the “quinolone-resistance-determining regions” (QRDRs) have been shown to cause FQ-R. In M. tuberculosis, the most common FQ-R mutations alter codons 90 and 94 of gyrA, but substitutions are also found in codons 74, 88, 89, and 91 (4, 5). Drug resistance mutations generally impart a fitness cost manifested as reduced growth rates and lower virulence, which could be ameliorated by second-site compensatory mutations (6–8). Such compensatory evolution could play a pivotal role in the maintenance and spread of drug-resistant bacteria (9). Previous study has demonstrated low clustering rates for FQ-resistant clinical M. tuberculosis strains (10), suggesting that FQ-R mutations may somehow make them less likely to be transmitted, but little is known about the fitness costs of FQ-R and the evolution of possible compensatory mutations. Here, we used Mycobacterium aurum as a model organism for studying the fitness cost and compensatory evolution of FQ-R in M. tuberculosis. Compared to other mycobacteria used as models for tuberculosis research, M. aurum does not aggregate, which facilitates precise colony enumeration (11). Although fast growing and nonpathogenic, M. aurum is like M. tuberculosis for FQ-R, and its QRDRs of gyrA and gyrB show amino acid identities of 95 and 97.56%, respectively, with those of M. tuberculosis.

We generated a total of 144 levofloxacin-resistant M. aurum strains from three rounds of selection with 2-fold increasing concentrations of levofloxacin. As shown in Table 1, 45 single mutants were isolated from the wild-type (WT) strain, while the 92 double and 7 triple mutants were derived from strains with single and double mutations, respectively. Primers for amplifying and sequencing of the QRDRs of gyrA and gyrB are described in Table S1 in the supplemental material. Levofloxacin MIC values were determined using broth microdilution method (12). As shown in Table 1, most levofloxacin resistance mutations occurred in codons 90 and 94 of gyrA, and resistance levels increased with mutation accumulation. To further investigate whether FQ-R influences the bacterial fitness, we analyzed the growth kinetics by recording the optical density at 600 nm (OD600) of a WT control and levofloxacin-resistant M. aurum strains with different mutations. Most of the mutant strains (23/29, 79%) had little or no growth defect (Fig. 1a), but six mutant strains showed growth rates substantially less than that of the WT strain (Fig. 1b). The gyrA mutations in these strains were G88C, G88D, D94N+D89G, D94G+D89N, D94Y+D89N, and D94Y+G88C (Table 1). To quantify the relative fitness of these six mutant strains compared to WT strain, we performed an in vitro competition assay, as previously described (13), by inoculating equal volumes of WT and mutant cultures (OD600 = 1) at a 1:100 dilution, and counting colonies at baseline (0 h) and endpoint (72 h). All six slow-growing mutants showed significantly lower fitness compared to the WT strain (Fig. 1e), but the strain that was least fit had the gyrA G88C substitution, as also seen in Mycobacterium smegmatis (14). Interestingly, the fitness of this G88C mutant was partially restored by the acquisition of a second gyrA D94Y substitution, suggesting an intragenic compensatory mechanism.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

Mutation and levofloxacin MICs of levofloxacin-resistant M. aurum strains

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Fitness costs and compensation of mutant M. aurum strains. (a and b) Graphs show the growth curves of M. aurum strains in nonantibiotic 7H9 broth. The OD600 is plotted as a function of time. Mutations at codons 88, 89, 90, 91, and 94 are located in the gyrA gene, and mutations at codons 500 and 538 are located in the gyrB gene. The WT and single mutants are indicated by a circle, while double and triple mutants are indicated by triangles and asterisks, respectively. (c and d) Growth curves of M. aurum strains after 0 (solid lines) and 18 (dashed lines) growth cycles in nonantibiotic and 0.2 μg/ml of levofloxacin 7H9 broth, respectively. (e and f) Relative fitness (e) and ATP levels (f) of M. aurum strains after 0 (dark shading) and 18 (light shading) growth cycles, respectively. The results show the means ± the standard deviations of three independent experiments, and the exact P values are listed above the pairs of data (paired t test).

We then experimentally evolved the six slow-growing mutants in the laboratory, with the WT strain as a control. Eight independent cultures for each strain were grown in antibiotic-free 7H9 broth for 3 days and then serially passaged by transferring 3 μl of culture into 3 ml of fresh medium to initiate the next 3-day growth cycle. After 18 growth cycles, five of the six evolved mutant strains showed growth rates that were restored to that of the WT and improved fitness compared to their mutant parents (Fig. 1c to e). The only mutant that did not evolve restored fitness after 18 growth cycles was the strain with the single G88C substitution. Illumina whole-genome sequencing (WGS) found that all five evolved fitness-restored strains convergently had frameshift insertions in the glgC gene, which encodes an ADP-glucose pyrophosphorylase (AGPase) (Table S2). The evolved strains maintained the same MICs as their slower growing ancestors, indicating that the compensatory mutations had no impact on drug resistance (Table S2). In addition, WGS identified mutations in 12 other genes in the evolved strains, including some from the passaged WT strain (Table S3), but none of these mutations were found in evolved strains from more than one original mutant.

FQ-R mutations have been reported to alter the enzymatic activity of the ATP-dependent DNA gyrase (15). Because the AGPase, encoded by glgC gene, is involved in the ATP-consuming process of glycogen synthesis (16), frameshift insertions that inactivate the glgC gene might reduce glycogen synthesis and therefore ATP consumption. Consistent with this explanation, cellular ATP concentrations, measured using an ATP assay kit (Beyotime, Shanghai, China) according to the manufacturer’s instructions, were significantly higher in all faster growing evolved strains than in their pre-evolved mutant parents (paired t test, P < 0.01) (Fig. 1f). The higher ATP levels could perhaps increase the activity of the ATP-dependent DNA gyrase, thus compensating for a putatively reduced functional gyrase capacity in the low fitness mutants. Since the GlgC proteins of M. aurum and M. tuberculosis are highly similar (identity, 91.34%), we searched for glgC mutations in a data set of more than 700 clinical FQ-resistant M. tuberculosis strains but identified only one strain, with gyrA D94G plus gyrB A504V substitutions, that had an insertion mutation in the glgC gene. It is possible that the putative compensatory mutations in the glgC gene are not found in clinical M. tuberculosis isolates because low fitness FQ-R mutant strains would not survive long enough in a clinical setting to develop a compensatory mutation. However, occasional clinical strains are found with the fitness-costing mutations we describe, but they may have compensatory mutations that, due to differences in the biology of M. tuberculosis, are distinct from the AGPase inactivating insertions found in M. aurum. The reports that FQ-R strains are less frequently transmitted could indicate that the more common FQ-R mutations have subtle fitness costs that we could not appreciate through in vitro studies of M. aurum but may affect the relative abilities of M. tuberculosis strains to cause disease.

In conclusion, we demonstrated that some levofloxacin-resistant M. aurum strains with mutations in gyrA showed fitness costs that were compensated with the acquisition of insertions into the glgC gene. The fitness compensated strains showed higher ATP concentrations than the WT strain, perhaps due to decreased ATP consumption resulting from the absence of the glgC encoded AGPase. This study represents a first step toward a better understanding of the fitness effects of FQ-R mutations in mycobacteria. Further studies are warranted to investigate the molecular basis of fitness costs and the compensatory mechanisms in FQ-R mycobacteria.

Data availability.The WGS data have been submitted to the Sequence Read Archive of the National Center for Biotechnology Information as recalibrated BAM files (accession number PRJNA598519).

ACKNOWLEDGMENTS

This study was supported by the Natural Science Foundation of China (81661128043 and 81871625 to Q.G. and 81701975 to Q.L.) and the National Science and Technology Major Project of China (2017ZX10201302 and 2018ZX10715012).

FOOTNOTES

    • Received 5 February 2020.
    • Returned for modification 5 March 2020.
    • Accepted 25 May 2020.
    • Accepted manuscript posted online 1 June 2020.
  • Supplemental material is available online only.

  • Copyright © 2020 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    World Health Organization. 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf.
  2. 2.↵
    1. Bhering M,
    2. Duarte R,
    3. Kritski A
    . 2019. Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000–2016. PLoS One 14:e0218299. doi:10.1371/journal.pone.0218299.
    OpenUrlCrossRef
  3. 3.↵
    1. Mayer C,
    2. Takiff H
    . 2014. The molecular genetics of fluoroquinolone resistance in Mycobacterium tuberculosis. Microbiol Spectr 2:MGM2-0009–2013.
    OpenUrl
  4. 4.↵
    1. Sun Z,
    2. Zhang J,
    3. Zhang X,
    4. Wang S,
    5. Zhang Y,
    6. Li C
    . 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 31:115–121. doi:10.1016/j.ijantimicag.2007.10.014.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Ergeshov A,
    2. Andreevskaya SN,
    3. Larionova EE,
    4. Smirnova TG,
    5. Chernousova LN
    . 2017. The spectrum of mutations in genes associated with resistance to rifampicin, isoniazid, and fluoroquinolones in the clinical strains of Mycobacterium tuberculosis reflects the transmissibility of mutant clones. Mol Biol (Mosk) 51:595–602. doi:10.7868/S0026898417030041.
    OpenUrlCrossRef
  6. 6.↵
    1. Comas I,
    2. Borrell S,
    3. Roetzer A,
    4. Rose G,
    5. Malla B,
    6. Kato-Maeda M,
    7. Galagan J,
    8. Niemann S,
    9. Gagneux S
    . 2011. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 44:106–110. doi:10.1038/ng.1038.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Melnyk AH,
    2. Wong A,
    3. Kassen R
    . 2015. The fitness costs of antibiotic resistance mutations. Evol Appl 8:273–283. doi:10.1111/eva.12196.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Gygli SM,
    2. Borrell S,
    3. Trauner A,
    4. Gagneux S
    . 2017. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev 41:354–373. doi:10.1093/femsre/fux011.
    OpenUrlCrossRef
  9. 9.↵
    1. Merker M,
    2. Barbier M,
    3. Cox H,
    4. Rasigade JP,
    5. Feuerriegel S,
    6. Kohl TA,
    7. Diel R,
    8. Borrell S,
    9. Gagneux S,
    10. Nikolayevskyy V,
    11. Andres S,
    12. Nubel U,
    13. Supply P,
    14. Wirth T,
    15. Niemann S
    . 2018. Compensatory evolution drives multidrug-resistant tuberculosis in Central Asia. Elife 7:e38200. doi:10.7554/eLife.38200.
    OpenUrlCrossRef
  10. 10.↵
    1. Hu Y,
    2. Mathema B,
    3. Wang W,
    4. Kreiswirth B,
    5. Jiang W,
    6. Xu B
    . 2011. Population-based investigation of fluoroquinolones resistant tuberculosis in rural eastern China. Tuberculosis (Edinb) 91:238–243. doi:10.1016/j.tube.2011.03.001.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Namouchi A,
    2. Cimino M,
    3. Favre-Rochex S,
    4. Charles P,
    5. Gicquel B
    . 2017. Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery. BMC Genomics 18:530. doi:10.1186/s12864-017-3924-y.
    OpenUrlCrossRef
  12. 12.↵
    1. Sugahara K
    . 1988. Microdilution broth procedure. Rinsho Byori 36:1261–1267.
    OpenUrlPubMed
  13. 13.↵
    1. Luo T,
    2. Yuan J,
    3. Peng X,
    4. Yang G,
    5. Mi Y,
    6. Sun C,
    7. Wang C,
    8. Zhang C,
    9. Bao L
    . 2017. Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis. J Antimicrob Chemother 72:1893–1900. doi:10.1093/jac/dkx110.
    OpenUrlCrossRef
  14. 14.↵
    1. Borrell S,
    2. Teo Y,
    3. Giardina F,
    4. Streicher EM,
    5. Klopper M,
    6. Feldmann J,
    7. Muller B,
    8. Victor TC,
    9. Gagneux S
    . 2013. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med Public Health 2013:65–74. doi:10.1093/emph/eot003.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Yamaguchi T,
    2. Yokoyama K,
    3. Nakajima C,
    4. Suzuki Y
    . 2017. Quinolone resistance-associated amino acid substitutions affect enzymatic activity of Mycobacterium leprae DNA gyrase. Biosci Biotechnol Biochem 81:1343–1347. doi:10.1080/09168451.2017.1314757.
    OpenUrlCrossRef
  16. 16.↵
    1. Cereijo AE,
    2. Diez MDA,
    3. Costa JSD,
    4. Alvarez HM,
    5. Iglesias AA
    . 2016. On the kinetic and allosteric regulatory properties of the ADP-glucose pyrophosphorylase from Rhodococcus jostii: an approach to evaluate glycogen metabolism in oleaginous bacteria. Front Microbiol 7:830. doi:10.3389/fmicb.2016.00830.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant Mycobacterium aurum
Rui Pi, Qingyun Liu, Howard E. Takiff, Qian Gao
Antimicrobial Agents and Chemotherapy Jul 2020, 64 (8) e00224-20; DOI: 10.1128/AAC.00224-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant Mycobacterium aurum
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant Mycobacterium aurum
Rui Pi, Qingyun Liu, Howard E. Takiff, Qian Gao
Antimicrobial Agents and Chemotherapy Jul 2020, 64 (8) e00224-20; DOI: 10.1128/AAC.00224-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

levofloxacin
resistance
fitness cost
compensatory mutation
mycobacteria

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596